Van Hulzen Asset Management LLC Invests $3.21 Million in Edwards Lifesciences Corporation $EW

Van Hulzen Asset Management LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel.com reports. The firm purchased 35,500 shares of the medical research company’s stock, valued at approximately $3,211,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at about $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $26,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.8%

Shares of NYSE EW opened at $90.53 on Tuesday. The company’s 50-day simple moving average is $89.30 and its 200-day simple moving average is $84.74. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The firm has a market cap of $52.13 billion, a price-to-earnings ratio of 52.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock valued at $2,219,390 over the last ninety days. Company insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.